<DOC>
	<DOCNO>NCT01650051</DOCNO>
	<brief_summary>The primary objective evaluate safety efficacy Phenazopyridine HCl Tablets , USP 200 mg short term analgesic treatment pain upon urination associate Uncomplicated Urinary Tract Infections ( uUTI ) . The secondary exploratory objective evaluate safety efficacy Phenazopyridine HCl Tablets , USP 200 mg short term analgesic treatment burn upon urination associate uUTI .</brief_summary>
	<brief_title>Safety Efficacy Phenazopyridine Hydrochloride Tablets , USP 200 mg Analgesic Short-Term Treatment Female Subjects Suffering From Moderate-to-Severe Pain Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections ( uUTI )</brief_title>
	<detailed_description>Subjects make separate self-assessments severity pain burn upon urination use NRS self-assessments discomfort use GSAS designate interval 24 hour . Subjects rate effectiveness study medication use SASMS designate interval 24 hour .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Is willing able provide understand write informed consent study . Is female 18 year age older . Has clinical diagnosis uncomplicated urinary tract infection ( uUTI ) . Has report history indicate diagnosis cystitis urethritis . Has positive urine dipstick test show presence nitrate leukocyte esterase . Has moderate severe pain ( score 4 10 inclusive NRS ) burning ( score 410 , inclusive NRS ) upon urination . Is willing able understand comply requirement study . Each female subject childbearing potential ( exclude woman surgically sterilize postmenopausal least 2 year ) must negative urine pregnancy test Screening must willing use acceptable form birth control study . For purpose trial , follow consider acceptable method birth control : oral contraceptive , contraceptive patch , contraceptive implant , vaginal contraceptive , double barrier method ( eg , condom spermicide ) , contraceptive injection ( Depoprovera® ) , intrauterine device ( IUD ) , hormonal IUD ( Mirena® ) , abstinence document second acceptable method birth control subject become sexually active . Is pregnant breastfeed study . Has diagnosis urinary tract kidney disorder uUTI . Has diagnosis pyelonephritis ( kidney infection low uUTI spread upper tract ) . Has take analgesic within 1 day prior Visit 1 . Has take systemic antiinfectives within 7 day prior Visit 1 . Has history G6PD deficiency hemolytic anemia . Has know history anatomical genitourinary ( GU ) anomalies GU surgery within 6 month prior Visit 1 . Has chronic infection urinary tract require intravenous pyelogram ( IVP ) , ultrasound , cystoscopy . Is unable comprehend language inform consent selfevaluation scale . Has serious acute illness ( e.g. , pneumonia ) untreated unstable medical illness would likely interfere assessment uUTI . Has receive investigational medication part drug trial within 3 month prior Visit 1 . Is currently participate clinical study . Has history severe drug allergy hypersensitivity , include phenazopyridine HCl component study medication . Consumes excessive amount alcohol , abuse drug , condition would compromise compliance protocol . Previous participation study . Any clinically significant condition situation , opinion Investigator would interfere study evaluation optimal participation study . Prior use phenazopyridine product within 3 year enrollment . Is employee direct relative study site Investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>